Form 4: Lenz Therapeutics CEO Granted Stock Options
SEC Form 4 Filing
Lenz Therapeutics CEO, Evert Schimmelpennink, was granted stock options for 279,100 shares, vesting over a period of time.
Summary
- Evert Schimmelpennink, CEO of Lenz Therapeutics, was granted stock options to purchase 279,100 shares of common stock.
- The options have an exercise price of $26.34 per share.
- The options vest over time, with 25% vesting after one year from the vesting commencement date of January 9, 2025, and the remaining shares vesting monthly over the following 36 months.
- The options expire on January 8, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotech industry.
- The vesting schedule of 4 years is typical for such grants, aligning with long-term value creation.
- The exercise price is set at a specific value, which is common practice.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of the earliest transaction and vesting commencement date for the stock options. |
| 01/13/2025 | Date of the Power of Attorney execution. |
| 01/08/2035 | Expiration date of the stock options. |
Keywords
stock options, equity compensation, CEO, Lenz Therapeutics, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.